Bladder Cancer Diagnostics Market: as blue light cystoscopy adoption expands from academic urology centres into community practices through the Karl Storz Saphira platform and Medicare outpatient reimbursement reclassification, so Photocure Hexvix/Cysview converts a historically equipment-only cystoscopy procedure into a per-procedure pharmaceutical consumable revenue stream, and so non-invasive urine biomarker tests anchored by Pacific Edge CxBladder AUA Level A evidence guideline inclusion establish a new clinical ordering category that reduces unnecessary cystoscopy referrals while generating recurring molecular diagnostic revenue from the NMIBC surveillance population.

The global bladder cancer diagnostics market size was USD 1.89 Billion in 2025 and is expected to register a revenue CAGR of 8.5% during the forecast period. Market revenue growth is driven by factors such as the rising global incidence of bladder cancer and the high surveillance burden of non-muscle invasive bladder cancer, the commercial expansion of blue light cystoscopy through the Photocure Hexvix/Cysview platform driven by Medicare outpatient reimbursement reclassification, as well as the clinical guideline validation of non-invasive urine biomarker tests as adjuncts to surveillance cystoscopy that create a new recurring molecular diagnostic revenue stream from the NMIBC follow-up population. The first driving factor is the high recurrence and surveillance burden of non-muscle invasive bladder cancer. NMIBC accounts for approximately 75% of all new bladder cancer cases at diagnosis and carries a 5-year recurrence rate of 50 to 70% and a 10 to 30% risk of progression to muscle-invasive disease, generating a lifelong surveillance cystoscopy schedule at 3-month, 6-month, and annual intervals per TURBT that drives the majority of cystoscopy device, Hexvix/Cysview photosensitising agent, and urine biomarker surveillance test revenue. The American Cancer Society estimated approximately 84,870 new bladder cancer cases and 17,420 deaths in the United States in 2025, establishing the incidence base that generates new diagnostic and initial staging revenue in addition to the surveillance volume from the existing NMIBC patient population under long-term follow-up. The second driving factor is the commercial acceleration of blue light cystoscopy through the Karl Storz Saphira high-definition platform and Medicare outpatient reimbursement reclassification. Photocure ASA disclosed in its FY2024 Annual Report that Hexvix/Cysview revenues grew 10% to NOK 487.9 Million and that 55 Saphira towers were placed in the US during 2024, with the US installed base of rigid BLC systems reaching 390 at year-end, and Photocure disclosed that Medicare reclassification in 2024 removed the outpatient BLC cost barrier that had previously confined Cysview use to academic centres where the drug cost was recoverable within the higher-complexity inpatient case payment. The third driving factor is the clinical guideline inclusion of non-invasive urine biomarker tests as validated cystoscopy adjuncts. Pacific Edge disclosed that its CxBladder Triage test is included in the American Urological Association Microhematuria Guideline as the first and only urine-based genomic biomarker test recommended with Level A evidence, establishing a guideline-backed ordering trigger for non-invasive urine biomarker testing before cystoscopy referral in microhematuria patients. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each Saphira rigid blue light cystoscopy system installed at a urology practice generates a per-procedure Cysview photosensitising agent consumable revenue stream that compounds in value as the installed system performs more BLC procedures per year, which allows Photocure to grow Cysview revenue at existing installed accounts without placing additional capital equipment. Once a urology practice has installed a Saphira system and urologists have adopted blue light cystoscopy for initial NMIBC diagnosis and TURBT, each subsequent surveillance cystoscopy performed on the Saphira system at that account adds incremental Cysview drug revenue without requiring a new equipment placement decision from the hospital capital budget, so the per-account Cysview revenue compounds as the caseload at established Saphira accounts grows and as the proportion of surveillance cystoscopies performed under blue light increases. As a result, Photocure's commercial strategy concentrates around deepening Cysview utilisation rates at the 390 established Saphira accounts rather than relying solely on new account placement, and the forecast tilts toward established BLC platform infrastructure accounts that generate recurring per-procedure consumable revenue rather than toward white light cystoscopy accounts that generate only equipment and service contract revenue without a pharmaceutical consumable layer. For instance, in FY2024, Photocure reported Q4 2024 Hexvix/Cysview revenues grew 13% to NOK 128.6 Million, confirming that per-account utilisation rate growth is already compounding installed base revenue, one of more than a dozen quarters of consecutive Hexvix/Cysview revenue growth that demonstrates the durability of the per-procedure pharmaceutical consumable model within the BLC installed base. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the commercial acceleration of Photocure's blue light cystoscopy Cysview platform at community urology practices following Medicare's 2024 reclassification of blue light cystoscopy reimbursement, which removed the cost barrier that had previously prevented outpatient urology practices from recovering the Cysview photosensitising agent cost within the procedure reimbursement framework. This model works only if the cystoscopy suite has a compatible blue light cystoscopy tower installed, and as the Karl Storz Saphira high-definition rigid BLC system enables superior flat carcinoma in situ detection and papillary tumour delineation compared with standard white light cystoscopy, the clinical evidence for BLC superiority in initial NMIBC detection and high-risk TURBT completeness justifies the Cysview drug cost to urology department quality improvement committees. Photocure disclosed in its FY2024 Annual Report that Hexvix/Cysview revenues grew 10% to NOK 487.9 Million, Cysview unit sales in the rigid segment grew 12%, the number of new rigid BLC towers grew 11% in the US from Q4 2023 to Q4 2024, and 55 Saphira towers were placed during 2024. The recent commercial record confirms the pace. In FY2024, Q4 Hexvix/Cysview revenues grew 13% to NOK 128.6 Million, reflecting accelerating commercial momentum, and Photocure announced a strategic agreement with Richard Wolf GmbH to develop a next-generation flexible blue light cystoscope, targeting reintroduction and growth of BLC in the surveillance cystoscopy setting where the flexible format is preferred over rigid for patient comfort in office-based quarterly or semi-annual NMIBC recurrence monitoring. The effect on the market is a progressive conversion of the US cystoscopy procedure revenue base from a hardware-only revenue model toward a pharmaceutical consumable plus hardware model where each installed Saphira system generates recurring per-procedure Cysview drug revenue that compounds with utilisation rate as more cystoscopies at each installed account are performed under blue light. These are some of the key factors driving revenue growth of the market.

The second driver is the clinical guideline validation of non-invasive urine biomarker tests as evidence-based alternatives to reflexive cystoscopy referral in the microhematuria evaluation and NMIBC surveillance pathway, supported by Level A evidence guideline inclusion that creates a guideline-backed ordering justification for urologists in markets where clinical practice guideline endorsement is a prerequisite for institutional procurement and insurance reimbursement approval. Pacific Edge disclosed that CxBladder Triage went live in Kaiser Permanente electronic medical records across all urology medical centres in the Southern California Permanente Medical Group in November 2023, representing a major commercial milestone of EMR integration at a large integrated healthcare system that generates automated order eligibility for CxBladder at point-of-care for urologists managing microhematuria patient populations. In March 2023, Nonacus launched GALEAS Bladder in the United Kingdom, providing a urine-based NGS molecular triage test for haematuria evaluation that reduces the need for cystoscopy referral in patients with low molecular probability of bladder cancer, and in January 2024, Advanced Genomics Asia Pacific and Cancer Precision Medicine Inc. collaborated to launch GALEAS Bladder in Japan as an NGS-based non-invasive diagnostic, extending commercial reach into a market where bladder cancer incidence is increasing and molecular diagnostic adoption is accelerating. In November 2023, Nucleix received national reimbursement approval from the Dutch Healthcare Authority for its Bladder EpiCheck urine methylation DNA biomarker test effective January 1, 2024, making the Netherlands the first European country to provide national payer reimbursement for a non-invasive urine DNA methylation test for bladder cancer, establishing the European reimbursement precedent that Menarini Diagnostics will leverage through its September 2024 exclusive European Bladder EpiCheck distribution agreement across Germany, France, Italy, Spain, and other European markets. The effect on the market is the creation of a clinically validated non-invasive urine biomarker diagnostic category that generates recurring molecular test revenue from the NMIBC surveillance population at a cost per test of USD 200 to USD 600, substantially lower than the procedural cost of surveillance cystoscopy, while providing urologists with a guideline-endorsed tool for risk stratifying microhematuria patients before the cystoscopy referral decision. These are some of the key factors driving revenue growth of the market.

Pacific Edge CxBladder Triage holds the distinction of being the first and only urine-based genomic biomarker test included in the American Urological Association Microhematuria Guideline with Level A supporting evidence, the highest evidence grade in AUA guideline methodology. The Kaiser Permanente Southern California EMR integration in November 2023, generating automated CxBladder order eligibility at point-of-care across all urology medical centres, demonstrates the commercial translation of guideline inclusion into institutional ordering infrastructure.

The third driver is the geographic expansion of premium bladder cancer diagnostic tools beyond the established US and Northern European markets into Asia Pacific, Latin American, and Middle Eastern markets through regulatory approvals, distribution agreements, and named patient access programmes that extend the commercial footprint of BLC and urine biomarker tests into markets with rising bladder cancer incidence driven by tobacco use, industrial carcinogen exposure, and ageing populations. In September 2024, Menarini Diagnostics and Nucleix entered a long-term exclusive distribution agreement for Bladder EpiCheck in Europe across Germany, France, Italy, Spain, and other European markets where Menarini has established urology and oncology distribution relationships, adding significant commercial infrastructure to Nucleix's European distribution capability following the Dutch NZA reimbursement success. In 2025, the Asieris Richard Wolf System Blue received approval in China for blue light cystoscopy, expanding BLC platform availability in China's growing tertiary hospital urology market where bladder cancer incidence from urbanisation and industrial carcinogen exposure is creating diagnostic demand that existing white light cystoscopy infrastructure cannot fully characterise for NMIBC staging. In September 2024, Photocure initiated a Named Patient Programme for Hexvix blue light cystoscopy in South Africa in collaboration with Equity Pharmaceuticals, extending BLC access into the African private hospital market ahead of formal regulatory approval and reimbursement pathways. The effect on the market is a gradual geographic diversification of bladder cancer diagnostic revenue away from the current North American and Northern European concentration, supporting CAGR above the organic volume growth rate in established markets as new geographic revenue streams contribute to the forecast period total. These are some of the key factors driving revenue growth of the market.

However, the bladder cancer diagnostics market faces adoption constraints from Medicare reimbursement uncertainty for urine biomarker surveillance tests and from the clinical primacy of white light cystoscopy as the diagnostic gold standard that limits displacement. Because Pacific Edge disclosed that the Novitas MAC extended its Local Coverage Determination timeline for Genetic Testing for Oncology through mid-2024, creating Medicare coverage uncertainty that constrained CxBladder commercial volume growth in the Medicare patient population and necessitated commercial restructuring to prioritise commercially insured territories, the dominant US payer's reimbursement uncertainty effectively caps the NMIBC surveillance cystoscopy reduction market for urine biomarker tests to commercially insured patients until a positive LCD is issued, limiting total addressable market to a fraction of the microhematuria evaluation and NMIBC surveillance population. White light cystoscopy primacy is a second constraint, since cystoscopy remains the only diagnostic modality enabling simultaneous visual inspection, biopsy, TURBT, and ureteral assessment that no urine biomarker test can replicate, sustaining cystoscopy procedure volume and limiting urine biomarker test displacement to adjunct applications rather than complete cystoscopy replacement across the NMIBC surveillance schedule. Iran-US sanctions and Strait of Hormuz supply chain disruptions are the third constraint, since they have maintained elevated costs for optical fibre components, LED light sources, and specialty photosensitising agent raw materials used in BLC equipment and Hexvix/Cysview manufacturing at European production facilities serving Middle Eastern and Latin American markets through 2026, raising capital equipment costs for BLC adoption in price-sensitive emerging markets that would otherwise represent new growth opportunities for Photocure's commercial expansion beyond its established US and European installed base. These factors substantially limit bladder cancer diagnostics market growth over the forecast period.

Non-muscle invasive bladder cancer stage is expected to account for a significantly large revenue share in the global bladder cancer diagnostics market during the forecast period

Based on cancer stage, the global bladder cancer diagnostics market is segmented into non-muscle invasive bladder cancer, muscle-invasive bladder cancer, locally advanced and metastatic, and surveillance and recurrence monitoring. Non-muscle invasive bladder cancer holds the largest revenue share at approximately 62% of 2025 market revenue, because NMIBC accounts for approximately 75% of all newly diagnosed bladder cancer cases and the 5-year recurrence rate of 50 to 70% and 10 to 30% progression risk to muscle-invasive disease generates the surveillance cystoscopy procedure schedule at 3-month, 6-month, and annual intervals that drives the majority of cystoscopy device, Hexvix/Cysview photosensitising agent, and urine biomarker surveillance test revenue. The surveillance and recurrence monitoring sub-stage represents the highest commercial value bladder cancer diagnostic patient cohort for non-invasive urine biomarker tests that can reduce the frequency of cystoscopy surveillance in low-risk NMIBC patients under long-term follow-up.

Based on regional analysis, the bladder cancer diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the 390-system US Saphira BLC installed base, the AUA guideline inclusion of CxBladder Triage with Level A evidence, and the concentration of leading bladder cancer diagnostic companies including Photocure's US commercial operations, Pacific Edge's CLIA-certified US laboratory network, and Cepheid's Danaher-backed US distribution infrastructure collectively anchor the highest per-capita advanced bladder cancer diagnostic adoption rate globally. The American Cancer Society's estimate of 84,870 new US bladder cancer cases in 2025 creates the patient volume that makes AI cystoscopy and molecular urine biomarker tools commercially viable, and Medicare outpatient BLC reimbursement reclassification in 2024 means new Saphira placements at community urology practices generate commercially recoverable per-procedure Cysview revenue from the first BLC procedure performed at each installed account. The concentration of urological oncology programme density at academic centres including MD Anderson, Memorial Sloan Kettering, and Johns Hopkins also means new bladder cancer diagnostic tools are validated and adopted in the United States first, ahead of European CE Mark or Asia Pacific regulatory approval.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and the Netherlands represent the three largest national bladder cancer diagnostics markets within Europe. The European Association of Urology guidelines recommend blue light cystoscopy for primary diagnosis and re-TURBT for high-risk NMIBC, establishing the clinical evidence framework for BLC adoption, with Photocure disclosing that more than one-third of European target urology accounts have received Saphira upgrades since 2023. The EU IVDR 2017/746 regulatory framework requires CE marking for urine biomarker diagnostic products sold in Europe, sustaining the competitive position of established IVD manufacturers with existing EU IVDR notified body certification. The result is steady rather than rapid growth in European bladder cancer diagnostics, shaped more by capital equipment refresh timelines and payer reimbursement approval processes for urine biomarker tests than by underlying clinical demand constraints.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national bladder cancer diagnostics markets within the region. Japan represents a growing commercial market for NGS-based urine biomarker diagnostics, demonstrated by the January 2024 GALEAS Bladder Japan launch by Advanced Genomics Asia Pacific and Cancer Precision Medicine Inc. providing Japanese urologists with a molecular urine biomarker triage option for haematuria evaluation, and the 2025 Asieris Richard Wolf System Blue approval in China for blue light cystoscopy represents the entry of BLC into China's tertiary hospital urology infrastructure, leaving more room for growth in Asia Pacific than in North America where BLC adoption at major academic urology centres is already well established.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national bladder cancer diagnostics markets within the region. Brazil maintains significant bladder cancer incidence driven by high rates of tobacco use and industrial chemical exposure, generating diagnostic demand at Brazilian tertiary urology centres where white light cystoscopy and urine cytology remain the primary diagnostic modalities, with private hospital networks including Sírio-Libanês and Albert Einstein Hospital representing the early-adopter accounts for advanced BLC and molecular urine biomarker diagnostic tools. Iran-US sanctions and the Strait of Hormuz supply chain disruptions have maintained elevated import costs for optical fibre components, LED light sources, and specialty photosensitising agent raw materials entering Latin American hospital urology supply chains through affected freight corridors through 2026, raising the total capital cost of BLC system installation at Latin American hospital urology departments beyond the reimbursable procedure revenue at current regional cystoscopy reimbursement rates.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and Egypt represent the primary commercial bladder cancer diagnostics markets within the region. Egypt has one of the highest bladder cancer incidences globally, historically associated with Schistosoma haematobium infection causing squamous cell carcinoma in the Nile Delta population alongside rising urothelial carcinoma from tobacco use, sustaining diagnostic demand at Egyptian tertiary urology centres. Saudi Arabia is the most established market on the continent for advanced BLC and molecular diagnostics investment, with Saudi Vision 2030 healthcare modernisation funding endoscopy equipment upgrades at tertiary hospital urology departments that create demand for Saphira BLC capital equipment at newly commissioned and refurbished Saudi hospital urology facilities, while sub-Saharan African markets are still building core endoscopy infrastructure before premium BLC system investment is feasible.